Table 2

Treatment-related adverse events in 20 phase I patients evaluable for toxicity of concurrent pembrolizumab+radiation therapy

Adverse event	Concurrent RT with Pembrolizumab, No. (%)
Adverse event	Grade 1	Grade 2	Grade 3	Grade 4
General
Fatigue	4 (20)	0	1 (5)	0
Malaise	1 (5)	1 (5)	0	0
Anorexia	0	1 (5)	0	0
Myalgia	1 (5)	1 (5)	0	0
Chills	1 (5)	0	0	0
Myositis	0	1 (5)	0	0
Pain	1 (5)	2 (10)	0	0
Weight loss	3 (15)	1 (5)	0	0
Dysgeusia	0	1 (5)	0	0
Dehydration	0	1 (5)	0	0
Headache	1 (5)	0	0	0
Flu-like Illness	1 (5)	0	0	0
Skin
Rash, maculopapular	3 (15)	0	1 (5)	0
Rash, pustular	1 (5)	0	0	0
Pruritus	0	0	1 (5)	0
Radiation dermatitis	0	1 (5)	0	0
Cardiac
Hypotension	0	1 (5)	0	0
Atrial fibrillation	1 (5)	0	0	0
Respiratory
Dyspnea	5 (25)	2 (10)	0	0
Cough	3 (15)	3 (15)	0	0
Pneumonitis	1 (5)	2 (10)	1 (5)	0
Hypoxia	0	1 (5)	0	0
Infection	0	0	1 (5)	0
Hemoptysis	0	1 (5)	0	0
Gastrointestinal
Dysphagia	1 (5)	1 (5)	0	0
Esophagitis	0	1 (5)	0	0
Colitis	0	1 (5)	0	0
Nausea	2 (10)	0	1 (5)	0
Vomiting	1 (5)	0	0	0
Diarrhea	2 (5)	0	0	0
Hematologic
Anemia	1 (5)	0	0	0
Thrombocytopenia	1 (5)	0	0	0
Investigations
AST elevation	1 (5)	0	0	0
ALT elevation	1 (5)	0	0	0
Creatinine elevation	2 (10)	0	0	0
Endocrine
Hypothyroidism	1 (5)	1 (5)	0	0
Hyperthyroidism	1 (5)	0	0	0